Arena Pharmaceuticals, Inc. ARNA announced today the initiation of dosing in a Phase 1 clinical trial of
APD334, a novel oral drug candidate that targets the sphingosine 1-phosphate
subtype 1 (S1P[1]) receptor for the potential treatment of autoimmune
diseases.
This randomized, double-blind and placebo-controlled Phase 1 trial will
evaluate the safety, tolerability and pharmacokinetics of single-ascending
doses of APD334 in up to 64 healthy adult volunteers.
"We are pleased to expand our clinical-stage pipeline by initiating a Phase 1
trial of APD334, and look forward to advancing this novel compound through our
validated development platform," said William R. Shanahan, M.D., Arena's
Senior Vice President and Chief Medical Officer. "APD334's selectivity for the
S1P[1] receptor has the potential to improve upon the adverse event profile of
currently available treatments for a spectrum of autoimmune diseases."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in